Product Highlight - TEZSPIRE

The next era of severe asthma management has emerged
Rise above the complexity

• The first and only approved biologic to treat across phenotypes and irrespective of biomarker levels^1-3

• Targets TSLP at the top of inflammatory cascade, reducing inflammation and airway hyperresponsiveness^2-4

• Early lung function improvement as early as week 2 and 230 mL improvement in FEV₁ from baseline at week 52³

• Delivers a 71% reduction in exacerbation²

• Demonstrates an 85% reduction in exacerbation-related hospitalisations in a broad patient population³

CASCADE: an exploratory, double-blind, randomized, placebo-controlled, parallel-group, phase 2 study for a planned 28 weeks in 116 patients with moderate-to-severe uncontrolled asthma. The primary endpoint was the change from baseline to the end of treatment in the number of airway submucosal inflammatory cells in bronchoscopic biopsy samples. PATHWAY: a double-blind, randomized, placebo-controlled, phase 2 study over a 52-week treatment period in 412 patients with moderate-to-severe asthma. The primary end point was the annualized rate of asthma exacerbations. NAVIGATOR: a double-blind, randomized, placebo-controlled, phase 3 study in 1,059 patients with severe, uncontrolled asthma for 52 weeks. The primary end point was the annualized rate of asthma exacerbations.

References:
1. Tezspire Hong Kong Packaging Insert, September 2023.
2. Corren J, Parnes JR, Wang L, et al. N Engl J Med. 2017;377(10):936-946.
3. Menzies-Gow A, Corren J, Bourdin A, et al. N Engl J Med. 2021;384(19):1800-1809.
4. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Lancet Respir Med. 2021;9(11):1299-1312.


For healthcare professionals only. Please visit contactazmedical.astrazeneca.com for (1) enquiring Medical Information (MI), (2) reporting Individual Case Safety Report (ICSR) and/or (3) reporting Product Quality Complaint (PQC) to AstraZeneca Hong Kong Limited.

HK-10412 03/06/2024